Serina Therapeutics, Inc. (SER) Financials

Serina Therapeutics, Inc. (SER) reported diluted earnings per share of -$1.91 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Serina Therapeutics, Inc. (SER) had EBITDA of -$23.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Serina Therapeutics, Inc. (SER) had $3.1M in cash and equivalents against $2.9M in long-term debt.

Serina Therapeutics, Inc. (SER) recorded an outflow of $18.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Serina Therapeutics, Inc. (SER) recorded an outflow of $18.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Serina Therapeutics, Inc. (SER) had $7.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Serina Therapeutics, Inc. (SER) invested $59K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Serina Therapeutics, Inc. (SER) invested $13.2M in research and development during fiscal year 2025.

Serina Therapeutics, Inc. (SER) had 12M shares outstanding as of fiscal year 2025.

Serina Therapeutics, Inc. (SER) had a current ratio of 1.71 as of fiscal year 2025, which is generally considered healthy.

Serina Therapeutics, Inc. (SER) had a return on assets of -276.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Serina Therapeutics, Inc. (SER) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $41.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Serina Therapeutics, Inc. (SER) trades at 322x sales, its market capitalization divided by $130K revenue, FY2025. The market capitalization is $41.9M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Serina Therapeutics, Inc. (SER) held $3.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $18.0M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Serina Therapeutics, Inc. (SER) has negative shareholder equity of -$37K as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Serina Therapeutics, Inc. (SER) has an Altman Z-Score of -20.14, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Serina Therapeutics, Inc. (SER) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Serina Therapeutics, Inc. (SER) reported a net loss of $19.2M while operations used $18.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Serina Therapeutics, Inc. (SER) reported an operating loss of $24.0M against $213K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.